It's also a matter of reputation. Everyone knows everyone and have read a few of the previous papers (or papers of the advisor/coworker/whatever). If the previous papers were good, it's a good signal to take a look at the new result. If the previous papers were dubious, you skim it in case there is something interesting, but may just ignore it.
[1] Perhaps the exception are medical trials, but they have a lot of rules and paperwork to avoid lying, error, misrepresentations and other nasty stuff. Anyway, after reading a lot of ivermectin preprints during peak pandemic, I'm not so sure.